GuidelineEndocrine reviews2023
International Consensus Guideline on Small for Gestational Age: Etiology and Management From Infancy to Early Adulthood.
Guideline in Endocrine reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 4 syntheses or guidelines pooled it, 150 citations in OpenAlex.
- Placental Stiffness Measured by Sonoelastography in Fetal Growth Restriction: A Systematic Review and Meta-Analysis.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2026Pooled it
- 46,XY DSD with Partial Gonadal Dysgenesis and Growth Failure in a Patient with 3q27.1 Microdeletion: Candidate Gene Curation After Exhaustive Literature Review.International journal of molecular sciences · 2026Pooled it
- Carbohydrate and lipid metabolism in neonates and children born SGA. A systematic review and metanalysis.Endocrine · 2025Pooled it
- Effects of long-term treatment with recombinant growth hormone on growth outcome in children born small for gestational age: a systematic review.Reviews in endocrine & metabolic disorders · 2025Pooled it
- A Phase 2 Study of PEGylated Recombinant Human Growth Hormone for 52 Weeks in Short Children Born Small for Gestational Age in China.Clinical endocrinology · 2025Trial
- Effectiveness of Recombinant Human Growth Hormone Therapy in Small-for-Gestational-Age Children With Short Stature: A Stratified Analysis Based on Genetic Variant Status.Clinical endocrinology · 2026Article
- Prenatal exposure to wildfire fine particulate matter and fetal growth outcomes in the United States: Findings from the ECHO Cohort.Environmental epidemiology (Philadelphia, Pa.) · 2026Article
- Phenotyping and hierarchical clustering in genetically unresolved DSD identifies distinct multisystem clinical subgroups-a DSDgene study.Journal of the Endocrine Society · 2026Article
- Diagnosis and management of Silver-Russell syndrome: second international consensus statement.Nature reviews. Endocrinology · 2026Review
- Article
- BMI-SDS Changes During GnRHa Therapy in 150 Girls with Idiopathic Central Precocious Puberty: Follow-up Through Final HeightJournal of clinical research in pediatric endocrinology · 2026Article
- Interpreting growth trajectories under conventional therapy in pediatric X-linked hypophosphatemia.Pediatric nephrology (Berlin, Germany) · 2026Article
- Size in small-for-gestational-age neonates correlates with insulin-like growth factor-binding protein proteolysis and insulin-like growth factor-I bioavailability.Journal of the Endocrine Society · 2026Article
- PRKAR1A-related acrodysostosis with partial growth hormone deficiency: 18-month response to recombinant human growth hormone.Hormones (Athens, Greece) · 2026Review
- Optimizing Feeding Practices Improves Outcomes During Early Childhood in Former Small for Gestational Age (SGA) Infants.Nutrients · 2026Article
- Growth Hormone Therapy in Children Born Small for Gestational Age with Persistent Short Stature: Lessons Learned from Real-World International Databases and Directions for Future Research.Hormone research in paediatrics · 2026Review
- Maternal metabolic determinants of accelerated infant weight gain in early life: assessing the combined effects of gestational diabetes and pre-pregnancy overweight.BMC public health · 2026Article
- Birth Weight Percentiles and Infant and Child Growth Dynamics.JAMA network open · 2026Article
- Placental abundances of IGF1, IGF2, IGFBP2, IGF2R, and PPARα are associated with birth weight.Journal of the Endocrine Society · 2026Article
- Early physical growth and neurodevelopment in full-term small for gestational age infants: reference points from propensity score matching and restricted cubic splines.Translational pediatrics · 2026Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 19 institutions in 13 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This International Consensus Guideline was developed by experts in the field of small for gestational age (SGA) of 10 pediatric endocrine societies worldwide. A consensus meeting was held and 1300 articles formed the basis for discussions. All experts voted about the strengths of the recommendations. The guideline gives new and clinically relevant insights into the etiology of short stature after SGA birth, including novel knowledge about (epi)genetic causes. Further, it presents long-term consequences of SGA birth and also reviews new treatment options, including treatment with gonadotropin-releasing hormone agonist (GnRHa) in addition to growth hormone (GH) treatment, as well as the metabolic and cardiovascular health of young adults born SGA after cessation of childhood GH treatment in comparison with appropriate control groups. To diagnose SGA, accurate anthropometry and use of national growth charts are recommended. Follow-up in early life is warranted and neurodevelopment evaluation in those at risk. Excessive postnatal weight gain should be avoided, as this is associated with an unfavorable cardiometabolic health profile in adulthood. Children born SGA with persistent short stature < -2.5 SDS at age 2 years or < -2 SDS at 3 to 4 years of age, should be referred for diagnostic workup. In case of dysmorphic features, major malformations, microcephaly, developmental delay, intellectual disability, and/or signs of skeletal dysplasia, genetic testing should be considered. Treatment with 0.033 to 0.067 mg GH/kg/day is recommended in case of persistent short stature at age of 3 to 4 years. Adding GnRHa treatment could be considered when short adult height is expected at pubertal onset. All young adults born SGA require counseling to adopt a healthy lifestyle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.